RNN On Other Exchanges
text size: T | T
Back to Snapshot
Company Description

Contact Info

15245 Shady Grove Road

Suite 455

Rockville, MD 20850

United States

Phone: 240-268-5300

Fax: 240-268-5310

Rexahn Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the discovery, development and commercialization of treatments for cancer. The company’s clinical pipeline features one oncology product candidate in Phase II clinical development, two oncology product candidates in Phase I clinical development, and additional compounds in pre-clinical development. Pipeline Drug Candidates Clinical Stage Pipeline The company’s three clinical stage drug candidates in active development are Archexin, RX-3117 and Supinoxin (RX-5902). Archexin Archexin is a potent inhibitor of the protein kinase Akt-1, which plays critical roles in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. Archexin has received ‘orphan drug’ designation from the U.S. Food and Drug Administration (the ‘FDA’) for renal cell carcinoma (RCC), glioblastoma, ovarian cancer, stomach cancer, and pancreatic cancer. The company has completed a pilot Phase IIa clinical trial of Archexin for the treatment of pancreatic cancer. It is conducting a Phase IIa proof-of-concept clinical trial of Archexin in patients with metastatic renal cell carcinoma to evaluate its safety and efficacy. RX-3117 RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action, and the company believes it has therapeutic potential in a range of cancers, including pancreatic, bladder, colon, and lung cancer. The company completed an exploratory Phase I clinical study of RX-3117 that showed a level of oral bioavailability of RX-3117 in humans with no adverse effects reported. The company is conducting a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in patients with solid tumors. RX-3117 has received orphan drug designation from the FDA for pancreatic cancer. Supinoxin (RX-5902) Supinoxin (RX-5902) is a potential small molecule inhibitor of phosphorylated-p68, a protein that the company believes plays a key role in cancer cell growth, progression and metastasis. The company is conducting a Phase I clinical trial of Supinoxin to evaluate its safety and efficacy in patients with solid tumors. The company also has one drug candidate in pre-clinical development, such as RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which the company believes might provide increased efficacy against tumors with potentially fewer side effects as a result of specific tumor targeting and increased stability in the body. In addition to its drug development efforts, the company is also working on proprietary research technologies, including its multi-target aimed ligands platform and nano-based drug delivery systems. The company’s ligand discovery platform, The Inhibitors of Multi-Expression Signals (TIMES), permits the company to identify potentially important targets that control multiple genes or signaling events in cancer cells. Its 3-D Gateway of Ligand Discovery (‘3-D GOLD’) integrates three-dimensional molecular modeling with databases of chemicals and proteins and ligand filtering and generation, which helps the company discover novel lead compounds. Pre-Clinical Pipeline RX-21101: Nano-polymer Anti-cancer Drug RX-21101 is an investigational anti-cancer nano-polymer drug that the company believes could mitigate some of the limitations of cytotoxic compounds, such as poor solubility and severe adverse reactions. Conjugating water-soluble and non-toxic N-(2-Hydroxypropyl) methacrylamide to conventional anti-cancer compounds might bolster efficacy while lowering toxicity by specific tumor targeting and increased stability in the body. In 2015, RX-21101 was selected by the National Cancer Institute's Nanotechnology Characterization Laboratory for its pre-clinical characterization program to facilitate the advancement of RX-21101 towards human clinical trials. Strategy The company’s strategy is to continue building a significant product pipeline of innovative drug candidates that the company intends to commercialize alone or with partners. This strategy has various key components, such as developing innovative therapeutics with the potential to b

Page 12Next Page

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies

Industry Analysis


Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.